Airain Ltd’s Tvardi Therapeutics TVRD Stock Holding History

Airain Ltd’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-552	Closed	-$335K	–	1107
2015 Q4	$335K	Buy	+552	New	+$303K	0.02%	572

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

CPM

Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Airain Ltd's TVRD Position: Q1 2016 in Review

Airain Ltd sold out of Tvardi Therapeutics (TVRD) in Q1 2016, closing a stake of 552 shares — an estimated $335K sold.

Airain Ltd first reported a position in TVRD in Q4 2015 and held it in 1 quarter. The position peaked at $335K in Q4 2015. 93 funds tracked by Wall St. Rank hold TVRD as of Q1 2016.

Airain Ltd reported no remaining Tvardi Therapeutics position as of Q1 2016 after selling out during the quarter.
Airain Ltd sold 552 Tvardi Therapeutics shares in Q1 2016, an estimated $335K.
Airain Ltd first reported a position in Tvardi Therapeutics in Q4 2015 and held it in 1 quarter.
Airain Ltd's Tvardi Therapeutics position peaked at $335K in Q4 2015.
93 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.